Skip to content
Wenlo
Sign in
← Markets

Neurocrine Biosciences, Inc.

George J Morrow (Director) sells NBIX shares

4NBIXFiled Nov 3, 2026, 1:52 PM ET· Period Oct 30, 2026

About this filing

Neurocrine Biosciences, Inc. (NBIX) filed Form 4 (insider transaction) with the SEC on Nov 3, 2026. Form 4 reports a company insider’s trades in the company’s shares.

Key facts

Insider
George J Morrow · Director

Rule 10b5-1 plan · adopted May 26, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Oct 30, 2026M · exercise or conversion of a derivative+300$53.64$16,092.0010,686Direct
Oct 30, 2026S · open-market saleFootnotes F1−300$149.00$44,700.0010,386Direct
Nov 2, 2026M · exercise or conversion of a derivative+7,500$53.64$402,300.0017,886Direct
Nov 2, 2026S · open-market saleFootnotes F1, F2−1,900$144.98$275,452.6915,986Direct
Nov 2, 2026S · open-market saleFootnotes F1, F3−4,300$145.86$627,194.1311,686Direct
Nov 2, 2026S · open-market saleFootnotes F1, F4−1,300$146.76$190,783.0610,386Direct
Nov 3, 2026M · exercise or conversion of a derivative+7,200$53.64$386,208.0017,586Direct
Nov 3, 2026S · open-market saleFootnotes F1−100$158.18$15,818.0017,486Direct
Nov 3, 2026S · open-market saleFootnotes F1−100$162.05$16,205.0017,386Direct
Nov 3, 2026S · open-market saleFootnotes F1, F5−600$163.71$98,224.9816,786Direct
Nov 3, 2026S · open-market saleFootnotes F1, F6−1,226$164.74$201,971.4915,560Direct
Nov 3, 2026S · open-market saleFootnotes F1, F7−908$165.71$150,461.0514,652Direct
Nov 3, 2026S · open-market saleFootnotes F1, F8−1,466$166.77$244,491.8613,186Direct
Nov 3, 2026S · open-market saleFootnotes F1, F9−1,500$167.72$251,587.2011,686Direct
Nov 3, 2026S · open-market saleFootnotes F1, F10−1,300$168.53$219,092.2510,386Direct
Oct 30, 2026M · exercise or conversion of a derivativeNon-Qualified Stock OptionFootnotes F11−300$0.00$0.0014,700Direct
Nov 2, 2026M · exercise or conversion of a derivativeNon-Qualified Stock OptionFootnotes F11−7,500$0.00$0.007,200Direct
Nov 3, 2026M · exercise or conversion of a derivativeNon-Qualified Stock OptionFootnotes F11−7,200$0.00$0.000Direct
Footnotes
  1. F1 The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $144.32 to $145.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $145.35 to $146.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. F4 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $146.38 to $147.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. F5 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.21 to $164.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. F6 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.22 to $165.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. F7 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.26 to $166.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  8. F8 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  9. F9 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.27 to $168.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  10. F10 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.27 to $169.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  11. F11 The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options were scheduled to expire on May 22, 2027.

More NBIX filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.